BTIG Research Initiates Coverage on ImmunityBio (NASDAQ:IBRX)

Equities researchers at BTIG Research began coverage on shares of ImmunityBio (NASDAQ:IBRX) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 54.95% from the stock’s current price.

Several other research analysts also recently issued reports on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. D. Boral Capital restated a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research report on Monday, March 9th. Jefferies Financial Group boosted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Finally, Piper Sandler reissued an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, ImmunityBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.40.

ImmunityBio Stock Performance

Shares of IBRX opened at $8.39 on Thursday. The company has a market cap of $8.63 billion, a price-to-earnings ratio of -22.08 and a beta of -0.03. The stock has a fifty day moving average price of $6.62 and a two-hundred day moving average price of $3.82. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $12.43.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. As a group, research analysts predict that ImmunityBio will post -0.92 EPS for the current fiscal year.

Insider Transactions at ImmunityBio

In other news, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the sale, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 501,967 shares of company stock worth $4,466,412. Corporate insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Slow Capital Inc. bought a new stake in shares of ImmunityBio during the 3rd quarter valued at $25,000. Envision Financial Planning LLC acquired a new position in shares of ImmunityBio in the 2nd quarter valued at $28,000. Diversify Advisory Services LLC bought a new position in shares of ImmunityBio in the 2nd quarter worth $27,000. Truist Financial Corp bought a new position in shares of ImmunityBio in the 3rd quarter worth $27,000. Finally, Swiss Life Asset Management Ltd acquired a new stake in shares of ImmunityBio during the third quarter worth $27,000. 8.58% of the stock is owned by institutional investors.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Anktiva approvals and sales growth are driving upside expectations — Zacks highlights recent approvals, growing U.S. uptake and global launches that set up a pivotal 2026 for Anktiva. IBRX Stock: Anktiva’s Approvals and What Comes Next
• Positive Sentiment: Company may benefit from a persistent BCG shortage that could accelerate Anktiva adoption in NMIBC; Zacks flags upcoming 2026 catalysts (FDA discussions, global launches, clinical milestones). IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Positive Sentiment: Operational progress: Benzinga reports ImmunityBio completed manufacturing engineering programs for its NK-cell therapy platform — a milestone that could ease scale-up and broaden pipeline value. Why Is ImmunityBio Stock Soaring On Friday?
• Positive Sentiment: Sell-side support: BTIG initiated coverage with a Buy and $13 price target, signaling analyst confidence in further upside from current levels. Benzinga
• Neutral Sentiment: Market narrative: MarketBeat/Barron’s coverage places ImmunityBio among small biotechs benefiting from powerful oncology launches (Anktiva), underscoring both growth potential and sector risk. Why 2 Small Biotechs May Hold the Key to New Cancer Treatments (IBRX)
• Negative Sentiment: Valuation and concentration risks: Zacks flags that the rally has pushed IBRX to roughly 33x sales for Anktiva and notes the premium assumes near-perfect commercialization; reliance on one product and a large 2025 net loss are key risk points. ImmunityBio Valuation: Paying 33x Sales for Anktiva

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.